Literature DB >> 18263881

Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.

Seok Ho Lee1, Kyu Chan Lee, Jin Ho Choi, Jae Hwan Oh, Jeong-Heum Baek, Se Hoon Park, Dong Bok Shin.   

Abstract

BACKGROUND: To determine complete resection and sphincter preservation rates, down-staging, local control and survival associated with concurrent chemoradiotherapy (CCRT) using a moderately high pelvic radiation dose before surgery in rectal cancer.
METHODS: Fifty-seven patients with histologically proven adenocarcinoma of the mid to lower rectum were treated using preoperative CCRT and surgery. Median radiation dose to the pelvis was 5400 cGy (5040-5580 cGy). CCRT was administered during the first and fifth weeks of radiotherapy with bolus intravenous 5-fluorouracil (5-FU) 400 mg/m(2)/day and leucovorin (LV) 20 mg/m(2)/day for 5 days. Surgery was attempted 4-8 weeks after completing preoperative CCRT. Post-operative chemotherapy was then added for up to four cycles of intravenous 5-FU and LV.
RESULTS: Toxicities during CCRT were generally mild and manageable: Grade 1/2 anemia, 3.5%; Grade 1/2 leukopenia, 45.6%; Grade 3 leukopenia, 3.5%; Grade 1/2 diarrhea, 22.8%; Grade 1/2 abdominal discomfort, 7%; and perianal skin reaction, 5.3%. No late complication requiring surgical intervention occurred. Complete surgical resection with a negative resection margin was achieved in 98.2% of patients, and the down-staging rate was 52.6% (30/57; 95% CI 39.6-65.6%). Complete pathologic response was obtained in 5.3% patients (3/57; 95% CI 0-11.1%) and in other 2 patients only sporadic tumor cells nests were noted in surgical specimens. The sphincter preservation rate was 77.2% (44/57; 95% CI 66.3-88.1%). Of 30 patients with tumors located within 5 cm from the anal verge, sphincter preservation was possible in 18 patients (60.0%; 95% CI 47.3-72.7%). With a median follow-up duration of 40 months, overall and disease-free survival (DFS) rates over 3 years were 91.8% (95% CI 85.5-98.2%) and 79.7% (95% CI 71.2-88.2%), respectively. At univariate analysis, significant factors for DFS was LN involvement status (P = 0.024). Local and distant failure rates over the same period were 5.3 and 21.1%, respectively.
CONCLUSIONS: Preoperative CCRT produced encouraging down-staging rates and was found to facilitate complete resection and sphincter saving in distal rectal cancer with acceptable toxicity. Further studies are warranted using this moderately high radiation dose to the pelvis to improve the local control.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18263881     DOI: 10.1093/jjco/hym164

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  3 in total

1.  Neoadjuvant treatment of mid-to-lower rectal cancer with oxaliplatin plus 5-fluorouracil and leucovorin in combination with radiotherapy: a Korean single center phase II study.

Authors:  Won-Suk Lee; Jeong-Heum Baek; Dong Bok Shin; Sun Jin Sym; Kwan An Kwon; Kyu Chan Lee; Seok Ho Lee; Dong Hae Jung
Journal:  Int J Clin Oncol       Date:  2012-02-18       Impact factor: 3.402

2.  What does absence of lymph node in resected specimen mean after neoadjuvant chemoradiation for rectal cancer.

Authors:  Won-Suk Lee; Seok Ho Lee; Jeong-Heum Baek; Woon Kee Lee; Jung Nam Lee; Na Rae Kim; Yeon Ho Park
Journal:  Radiat Oncol       Date:  2013-08-19       Impact factor: 3.481

3.  Are We Predicting Disease Progress of the Rectal Cancer Patients without Surgery after Neoadjuvant Chemoradiotherapy?

Authors:  Bo Young Oh; Jung Wook Huh; Woo Yong Lee; Yoon Ah Park; Yong Beom Cho; Seong Hyeon Yun; Hee Cheol Kim; Ho-Kyung Chun
Journal:  Cancer Res Treat       Date:  2017-07-03       Impact factor: 4.679

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.